StreetInsider.com News Articles

Form 4 RIGEL PHARMACEUTICALS For: May 26 Filed by: Ali-Jackson Kamil

Thu, 28 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260528/26567666.html

Form 4 RIGEL PHARMACEUTICALS For: May 26 Filed by: Ali-Jackson Kamil

Thu, 28 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260528/26567666.html

Rigel to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:45 a.m. ET in New York, NY.

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior

Rigel to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:05:00 -0400

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior

Rigel to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:05:00 -0400

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior

Rigel to Present at the Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:05:00 -0400

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior

Form 144 RIGEL PHARMACEUTICALS Filed by: Ali-Jackson Kamil

Tue, 26 May 2026 10:43:00 -0400

si-local-file:///var/storage/secattach/20260526/26547566.html

Form 144 RIGEL PHARMACEUTICALS Filed by: Ali-Jackson Kamil

Tue, 26 May 2026 10:43:00 -0400

si-local-file:///var/storage/secattach/20260526/26547566.html

Rigel to present cancer drug trial data at major medical conferences

Thu, 21 May 2026 17:36:42 -0400

Rigel Pharmaceuticals Inc (NASDAQ: RIGL) announced it will present clinical trial data for its cancer drugs at two major medical conferences in 2026, according to a press release statement.

The company will deliver an oral presentation at the American Society of Clinical Oncology Annual Meeting featuring final data from its Phase 3 AcceleRET-Lung clinical trial of GAVRETO (pralsetinib) as first-line treatment in patients with RET fusion-positive non-small cell lung cancer. The presentation is scheduled for May 29, 2026, in Chicago.

Additional poster presentations at both the ASCO Annual Meeting and the European Hematology Association 2026 Congress will include final analysis from the

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Thu, 21 May 2026 17:17:00 -0400

Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO^® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLC
Final analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in patients with advanced or metastatic RET-altered thyroid cancer to be presented in a poster session
Real-world data further supports the use of REZLIDHIA^® (olutasidenib) in patients with R/R mIDH1 AML that have received prior venetoclax